Literature DB >> 33501638

IL-36 cytokines and gut immunity.

Vu L Ngo1, Michal Kuczma1, Estera Maxim1, Timothy L Denning1.   

Abstract

Interleukin 36 (IL-36) constitutes a group of cytokines that belong to the IL-1 superfamily. Emerging evidence has suggested a role of IL-36 in the pathogenesis of many inflammatory disorders. Intriguingly, in the gastrointestinal tract, IL-36 has a rather complex function. IL-36 receptor ligands are overexpressed in both animal colitis models and human IBD patients and may play both pathogenic and protective roles, depending on the context. IL-36 cytokines comprise three receptor agonists: IL-36α, IL-36β and IL-36γ, and two receptor antagonists: IL-36Ra and IL-38. All IL-36 receptor agonists bind to the IL-36R complex and exert pleiotropic effects during inflammatory settings. Here, we first briefly review the processing and secretion of IL-36 cytokines. We then focus on the current understanding of the immunology effects of IL-36 in gut immunity. In addition, we also discuss the ongoing trials that aim to blockage IL-36R signalling for treating chronic intestinal inflammation and present some unexplored questions regarding IL-36 research.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  cytokine; inflammatory bowel diseases; interleukin; intestinal inflammation

Mesh:

Substances:

Year:  2021        PMID: 33501638      PMCID: PMC8114203          DOI: 10.1111/imm.13310

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.215


  71 in total

1.  IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist.

Authors:  Frank L van de Veerdonk; Angela K Stoeckman; Gouping Wu; Aaron N Boeckermann; Tania Azam; Mihai G Netea; Leo A B Joosten; Jos W M van der Meer; Ruyi Hao; Vassili Kalabokis; Charles A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

Review 2.  Targeting immune cell circuits and trafficking in inflammatory bowel disease.

Authors:  Markus F Neurath
Journal:  Nat Immunol       Date:  2019-06-24       Impact factor: 25.606

Review 3.  Fatigue in IBD: epidemiology, pathophysiology and management.

Authors:  Nienke Z Borren; C Janneke van der Woude; Ashwin N Ananthakrishnan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-04       Impact factor: 46.802

4.  IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells.

Authors:  Solenne Vigne; Gaby Palmer; Praxedis Martin; Céline Lamacchia; Deborah Strebel; Emiliana Rodriguez; Maria L Olleros; Dominique Vesin; Irene Garcia; Francesca Ronchi; Federica Sallusto; John E Sims; Cem Gabay
Journal:  Blood       Date:  2012-09-11       Impact factor: 22.113

5.  Current and emerging therapeutic targets for IBD.

Authors:  Markus Neurath
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-10-11       Impact factor: 46.802

6.  IL-36R ligands are potent regulators of dendritic and T cells.

Authors:  Solenne Vigne; Gaby Palmer; Céline Lamacchia; Praxedis Martin; Dominique Talabot-Ayer; Emiliana Rodriguez; Francesca Ronchi; Federica Sallusto; Huyen Dinh; John E Sims; Cem Gabay
Journal:  Blood       Date:  2011-08-22       Impact factor: 22.113

7.  Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity.

Authors:  Jennifer E Towne; Blair R Renshaw; Jason Douangpanya; Brian P Lipsky; Min Shen; Christopher A Gabel; John E Sims
Journal:  J Biol Chem       Date:  2011-09-29       Impact factor: 5.157

8.  Neutrophil-Derived Proteases Escalate Inflammation through Activation of IL-36 Family Cytokines.

Authors:  Conor M Henry; Graeme P Sullivan; Danielle M Clancy; Inna S Afonina; Dagmar Kulms; Seamus J Martin
Journal:  Cell Rep       Date:  2016-01-14       Impact factor: 9.423

9.  IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease.

Authors:  Jesper Falkesgaard Højen; Marie Louise Vindvad Kristensen; Amy S McKee; Megan Taylor Wade; Tania Azam; Lars P Lunding; Dennis M de Graaf; Benjamin J Swartzwelter; Michael Wegmann; Martin Tolstrup; Karsten Beckman; Mayumi Fujita; Stephan Fischer; Charles A Dinarello
Journal:  Nat Immunol       Date:  2019-08-19       Impact factor: 25.606

10.  Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation.

Authors:  Hal Blumberg; Huyen Dinh; Esther S Trueblood; James Pretorius; David Kugler; Ning Weng; Suzanne T Kanaly; Jennifer E Towne; Cynthia R Willis; Melanie K Kuechle; John E Sims; Jacques J Peschon
Journal:  J Exp Med       Date:  2007-10-01       Impact factor: 14.307

View more
  5 in total

1.  IL-36γ in enthesitis-related juvenile idiopathic arthritis and its association with disease activity.

Authors:  Sanjukta Majumder; Shivika Guleria; Amita Aggarwal
Journal:  Clin Exp Immunol       Date:  2022-06-11       Impact factor: 5.732

2.  IL-36β promotes anti-tumor effects in CD8+ T cells by downregulating micro-RNA let-7c-5p.

Authors:  Dongbao Li; Yang Huang; Zhuwen Yu; Jianglei Zhang; Chenrui Hu; Yanjin Bai; Jin Wang; Zhe Zhang; Jun Ouyang; Jin Zhou; Xin Zhao
Journal:  Ann Transl Med       Date:  2021-12

3.  Increased Levels of Interleukin-36 in Obesity and Type 2 Diabetes Fuel Adipose Tissue Inflammation by Inducing Its Own Expression and Release by Adipocytes and Macrophages.

Authors:  Gema Frühbeck; Javier Gómez-Ambrosi; Beatriz Ramírez; Amaia Mentxaka; Amaia Rodríguez; Sara Becerril; Gabriel Reina; Victor Valentí; Rafael Moncada; Camilo Silva; Victoria Catalán
Journal:  Front Immunol       Date:  2022-02-09       Impact factor: 7.561

4.  IL-36γ is secreted through an unconventional pathway using the Gasdermin D and P2X7R membrane pores.

Authors:  Laura D Manzanares-Meza; Claudia I Gutiérrez-Román; Albertana Jiménez-Pineda; Felipe Castro-Martínez; Genaro Patiño-López; Eunice Rodríguez-Arellano; Ricardo Valle-Rios; Vianney F Ortíz-Navarrete; Oscar Medina-Contreras
Journal:  Front Immunol       Date:  2022-08-18       Impact factor: 8.786

Review 5.  IL-36 Cytokines: Their Roles in Asthma and Potential as a Therapeutic.

Authors:  Hongna Dong; Yuqiu Hao; Wei Li; Wei Yang; Peng Gao
Journal:  Front Immunol       Date:  2022-07-12       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.